Inflammation-induced foam cell formation in chronic inflammatory disease

Immunology and Cell Biology

Volumn 93, Issue 8, 2015, Pages 683-693

  Angelovich, Thomas A ^a,b   Hearps, Anna C ^a,c   Jaworowski, Anthony ^a,c  

^a BURNET INSTITUTE   (Australia)

^b RMIT UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; CARDIOVASCULAR RISK; CELL ACTIVATION; FOAM CELL; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MACROPHAGE; MONOCYTE; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; ANIMAL; CHRONIC DISEASE; DISEASE MODEL; GENETICS; IMMUNOLOGY; LIPID METABOLISM; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FOAM CELLS; HUMANS; INFLAMMATION; LIPID METABOLISM; MACROPHAGE ACTIVATION; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS; TOLL-LIKE RECEPTORS;

EID: 84941874683     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.26     Document Type: Review

References (108)

1. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 2011; 31: 1506-1516.
2. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-561.
4. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck study. J Am Coll Cardiol 1999; 34: 1975-1981.
5. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P et al. Association of HIV infection, demographic and cardiovascular risk factors with allcause mortality in the recent HAART era. J Acquir Immune Defic Syndr 2010; 53: 102-106.
6. Freiberg MS, Chang CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622.
7. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
8. Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
9. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-732.
10. Westhorpe CLV, Dufour E, Maisa A, Jaworowski A, Crowe SM, Muller WA. Endothelial cell activation promotes foam cell formation by monocytes following transendothelial migration in an in vitro model. Exp Mol Pathol 2012; 93: 220-226.
11. Cros J, Cagnard N, Woollard K, Patey N, Zhang S-Y, Senechal B et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-386.
12. Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-1520.
13. Rothe G, Gabriel H, Kovacs E, Klucken J, Stöhr J, Kindermann W et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 1437-1447.
14. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277: 49982-49988.
15. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25.
16. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocytederived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101: 11779-11784.
17. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 2005; 115: 2192-2201.
18. Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M et al. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem 2012; 287: 11629-11641.
19. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203-214.
20. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for Men. Circulation 2008; 118: 2243-2251.
21. Nicolaou G, Goodall AH, Erridge C. Diverse bacteria promote macrophage foam cell formation via Toll-like receptor-dependent lipid body biosynthesis. J Atheroscler Thromb 2012; 19: 137-148.
22. Manning-Tobin JJ, Moore KJ, Seimon TA, Bell SA, Sharuk M, Alvarez-Leite JI et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol 2009; 29: 19-26.
23. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 416-421.
24. Groeneweg M, Kanters E, Vergouwe MN, Duerink H, Kraal G, Hofker MH et al. Lipopolysaccharide-induced gene expression in murine macrophages is enhanced by prior exposure to oxLDL. J Lipid Res 2006; 47: 2259-2267.
25. Zhu X, Lee J-Y, Timmins JM, Brown JM, Boudyguina E, Mulya A et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008; 283: 22930-22941.
26. van Tits LJH, Stienstra R, van Lent PL, Netea MG, Joosten LAB, Stalenhoef AFH. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2. Atherosclerosis 2011; 214: 345-349.
27. Spann Nathanael J, Garmire Lana X, McDonald Jeffrey G, Myers David S, Milne Stephen B, Shibata N et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 2012; 151: 138-152.
28. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
29. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4: e365.
30. Riddler S, Smit E, Cole S, Li R, Chmiel J, Dobs A et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-2982.
31. Bruunsgaard H, Skinhøj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-) and atherosclerosis. Clin Exp Immunol 2000; 121: 255-260.
32. Cesari M, BWJH Penninx, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation 2003; 108: 2317-2322.
33. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307.
34. Shi L, Zhang Z, Yu AM, Wang W, Wei Z, Akhter E et al. The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of noncoding and coding RNAs. PLoS ONE 2014; 9: e93846.
35. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
36. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206: 1558-1567.
37. Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS et al. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26: 843-853.
38. Szeto C-C, BC-H Kwan, Chow K-M, Lai K-B, Chung K-YLeung C-B et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008; 3: 431-436.
39. Armingohar Z, Jorgensen JJ, Kristoffersen AK, Abesha-Belay E, Olsen I. Bacteria and bacterial DNA in atherosclerotic plaque and aneurysmal wall biopsies from patients with and without periodontitis. J Oral Microbiol 2014; 6: e23408.
40. Desvarieux M, Demmer RT, Jacobs DR, Papapanou PN, Sacco RL, Rundek T. Changes in clinical and microbiological periodontal profiles relate to progression of carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study. J Am Heart Assoc 2013; 2: e000254.
41. Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis 2015; 211: 178-186.
42. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997; 96: 2144-2148.
43. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus infection increases development of atherosclerosis in Aapolipoprotein-E knockout mice. Atherosclerosis 2001; 156: 23-28.
44. Iwahashi M, Yamamura M, Aita T, Okamoto A, Ueno A, Ogawa N et al. Expression of toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1457-1467.
45. Wong CK, Wong PTY, Tam LS, Li EK, Chen DP, Lam CWK. Activation profile of Tolllike receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010; 159: 11-22.
46. Hernandez JC, Stevenson M, Latz E, Urcuqui-Inchima S. HIV type 1 infection upregulates TLR2 and TLR4 expression and function in vivo and in vitro. AIDS Res Hum Retroviruses 2012; 28: 1313-1328.
47. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and-independent cytokine secretion induced by minimally oxidized lowdensity lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005; 25: 1213-1219.
48. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278: 1561-1568.
49. Wiesner P, Choi S-H, Almazan F, Benner C, Huang W, Diehl CJ et al. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor {kappa}B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res 2010; 107: 56-65.
50. Howell KW, Meng X, Fullerton DA, Jin C, Reece TB, Cleveland JC. Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J Surg Res 2011; 171: e27-e31.
51. Dutertre C-A, Amraoui S, DeRosa A, Jourdain J-P, Vimeux L, Goguet M et al. Pivotal role of M-DC8+ monocytes from viremic HIV-infected patients in TNF overproduction in response to microbial products. Blood 2012; 120: 2259-2268.
52. Kowalski ML, Wolska A, Grzegorczyk J, Hilt J, Jarzebska M, Drobniewski M et al. Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis. Mediat Inflamm 2008; 2008: 132732.
53. Jiang W, Zhang L, Lang R, Li Z, Gilkeson G. Sex differences in monocyte activation in systemic lupus erythematosus (SLE). PLoS One 2014; 9: e114589.
54. Hearps AC, Martin GE, Angelovich TA, Cheng W-J, Maisa A, Landay AL et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell 2012; 11: 867-875.
55. Martin GE, Gouillou M, Hearps AC, Angelovich TA, Cheng AC, Lynch F et al. Ageassociated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLoS One 2013; 8: e55279.
56. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U. The CD14brightCD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum 2012; 64: 671-677.
57. Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Ziegler-Heitbrock HW. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood 1993; 82: 3170-3176.
58. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92.
59. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromes. Blood 2012; 120: 4599-4608.
60. Westhorpe CLV, Maisa A, Spelman T, Hoy JF, Dewar EM, Karapanagiotidis S et al. Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. Immunol Cell Biol 2014; 92: 133-138.
61. Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, Kalinowska M et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115: 161-167.
62. Edfeldt K, Swedenborg J, Hansson GK, Yan Z-q. Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-1161.
63. Ashida K, Miyazaki K, Takayama E, Tsujimoto H, Ayaori M, Yakushiji T et al. Characterization of the expression of TLR2 (Toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb 2005; 12: 53-60.
64. Wang L, Li D, Yang K, Hu Y, Zeng Q. Toll-like receptor-4 and mitogen-activated protein kinase signal system are involved in activation of dendritic cells in patients with acute coronary syndrome. Immunology 2008; 125: 122-130.
65. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102: 833-839.
66. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-636.
67. Hauer AD, de Vos P, Peterse N, ten Cate H, van Berkel TJC, Stassen FRM et al. Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr/mice. Cardiovasc Res 2006; 69: 280-288.
68. Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A et al. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006; 113: 929-937.
69. Kozarov EV, Dorn BR, Shelburne CE, Dunn WA, Progulske-Fox A. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 2005; 25: e17-e18.
70. Methe H, Kim J-O, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111: 2654-2661.
71. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E et al. Tolllike receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.
72. Cuaz-Pérolin C, Billiet L, Baugé E, Copin C, Scott-Algara D, Genze F et al. Antiinflammatory and antiatherogenic effects of the NF-B inhibitor acetyl-11-keto-boswellic acid in lps-challenged ApoE/mice. Arterioscler Thromb Vasc Biol 2008; 28: 272-277.
73. Higashimori M, Tatro JB, Moore KJ, Mendelsohn ME, Galper JB, Beasley D. Role of Toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 50-57.
74. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM et al. Lack of Tolllike receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-10684.
75. Naiki Y, Sorrentino R, Wong MH, Michelsen KS, Shimada K, Chen S et al. TLR/MyD88 and liver X receptor signaling pathways reciprocally control Chlamydia pneumoniaeinduced acceleration of atherosclerosis. J Immunol 2008; 181: 7176-7185.
76. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect Immun 1998; 66: 5067-5072.
77. Funk JL, Feingold KR, Moser AH, Grunfeld C. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis 1993; 98: 67-82.
78. Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect Immun 2007; 75: 753-759.
79. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94: 922-927.
80. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-232.
81. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine interferon-{alpha} and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007; 116: 2043-2052.
82. Li J, Fu Q, Cui H, Qu B, Pan W, Shen N et al. Interferon-priming promotes lipid uptake and macrophage-derived foam cell formation: A novel link between interferon-and atherosclerosis in lupus. Arthritis Rheum 2011; 63: 492-502.
83. Bernard MA, Han X, Inderbitzin S, Agbim I, Zhao H, Koziel H et al. HIV-derived ssRNA binds to TLR8 to induce inflammation-driven macrophage foam cell formation. PLoS One 2014; 9: e104039.
84. Salagianni M, Galani IE, Lundberg AM, Davos CH, Varela A, Gavriil A et al. Toll-Like receptor 7 protects from atherosclerosis by constraining 'inflammatory' macrophage activation. Circulation 2012; 126: 952-962.
85. Ye Q, Chen Y, Lei H, Liu Q, Moorhead J, Varghese Z et al. Inflammatory stress increases unmodified LDL uptake via LDL receptor: an alternative pathway for macrophage foam-cell formation. Inflamm Res 2009; 58: 809-818.
86. Li L-C, Varghese Z, Moorhead JF, Lee C-T, Chen J-B, Ruan XZ. Cross-talk between TLR4-MyD88-NF-B and SCAP-SREBP2 pathways mediates macrophage foam cell formation. Am J Physiol Heart Circ Physiol 2013; 304: H874-H884.
87. Choi S-H, Harkewicz R, Lee JH, Boullier A, Almazan F, Li AC et al. Lipoprotein accumulation in macrophages via Toll-like receptor-4-dependent fluid phase uptake. Circ Res 2009; 104: 1355-1363.
88. Lin H, Xiao Y, Chen G, Fu D, Ye Y, Liang L et al. HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Rheumatol Int 2011; 31: 1451-1458.
89. Lei L, Xiong Y, Chen J, Yang J-B, Wang Y, Yang X-Y et al. TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J Lipid Res 2009; 50: 1057-1067.
90. Schuster GU, Parini P, Wang L, Alberti S, Steffensen KR, Hansson GK et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 2002; 106: 1147-1153.
91. Baranova I, Vishnyakova T, Bocharov A, Chen Z, Remaley AT, Stonik J et al. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun 2002; 70: 2995-3003.
92. Chen S, Sorrentino R, Shimada K, Bulut Y, Doherty TM, Crother TR et al. Chlamydia pneumoniae-induced foam cell formation requires Myd88-dependent and-independent signaling and is reciprocally modulated by liver X receptor activation. J Immunol 2008; 181: 7186-7193.
93. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G et al. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003; 12: 805-816.
94. Kaplan R, Gan X, Menke JG, Wright SD, Cai T-Q. Bacterial lipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXR-independent pathway. J Lipid Res 2002; 43: 952-959.
95. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-219.
96. Thompson PA, Gauthier KC, Varley AW, Kitchens RL. ABCA1 promotes the efflux of bacterial LPS from macrophages and accelerates recovery from LPS-induced tolerance. J Lipid Res 2010; 51: 2672-2685.
97. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009; 119: 1135-1145.
98. van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002; 359: 37-42.
99. Feeney ER, McAuley N, O'Halloran JA, Rock C, Low J, Satchell CS et al. The expression of cholesterol metabolism genes in monocytes from HIV-infected subjects suggests intracellular cholesterol accumulation. J Infect Dis 2013; 207: 628-637.
100. Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH et al. ATMdependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006; 4: 377-389.
101. Karper JC, Ewing MM, Habets KLL, de Vries MR, Peters EAB, van Oeveren-Rietdijk AM et al. Blocking Toll-like receptors 7 and 9 Reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration. Arterioscler Thromb Vasc Biol 2012; 32: e72-e80.
102. Lu Z, Zhang X, Li Y, Jin J, Huang Y. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J Endocrinol 2013; 216: 61-71.
103. Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M et al. MicroRNA-155 deficiency results in deceased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2014; 34: 759-767.
104. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012; 122: 4190-4202.
105. Tian F-J, An L-N, Wang G-K, Zhu J-Q, Li Q, Zhang Y-Y et al. Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res 2014; 103: 100-110.
106. Huang RS, Hu GQ, Lin B, Lin ZY, Sun CC. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J Invest Med 2010; 58: 961-967.
107. Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D et al. MicroRNA146 represses endothelial activation by inhibiting proinflammatory pathways. EMBO Mol Med 2013; 5: 1017-1034.
108. Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci 2010; 119: 395-405.